JDP2, a Novel Molecular Key in Heart Failure and Atrial Fibrillation?
Gerhild EulerJens KockskämperRainer SchulzMariana S ParahulevaPublished in: International journal of molecular sciences (2021)
Heart failure (HF) and atrial fibrillation (AF) are two major life-threatening diseases worldwide. Causes and mechanisms are incompletely understood, yet current therapies are unable to stop disease progression. In this review, we focus on the contribution of the transcriptional modulator, Jun dimerization protein 2 (JDP2), and on HF and AF development. In recent years, JDP2 has been identified as a potential prognostic marker for HF development after myocardial infarction. This close correlation to the disease development suggests that JDP2 may be involved in initiation and progression of HF as well as in cardiac dysfunction. Although no studies have been done in humans yet, studies on genetically modified mice impressively show involvement of JDP2 in HF and AF, making it an interesting therapeutic target.
Keyphrases
- atrial fibrillation
- heart failure
- acute heart failure
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- left ventricular
- percutaneous coronary intervention
- transcription factor
- case control
- gene expression
- type diabetes
- single molecule
- oxidative stress
- cardiac resynchronization therapy
- high fat diet induced